Castration resistant prostate cancer is associated with increased blood vessel stabilization and elevated levels of VEGF and Ang-2
Tajana Tešan Tomić
Sahlgrenska Cancer Center, Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Göteborg, Sweden
Search for more papers by this authorHeléne Gustavsson
Sahlgrenska Cancer Center, Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Göteborg, Sweden
Search for more papers by this authorWanzhong Wang
Sahlgrenska Cancer Center, Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Göteborg, Sweden
Search for more papers by this authorKarin Jennbacken
Sahlgrenska Cancer Center, Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Göteborg, Sweden
Search for more papers by this authorKarin Welén
Sahlgrenska Cancer Center, Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Göteborg, Sweden
Search for more papers by this authorCorresponding Author
Jan-Erik Damber
Sahlgrenska Cancer Center, Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Göteborg, Sweden
Department of Urology, Sahlgrenska University Hospital, Bruna Stråket 11, SE-413 45 Göteborg, Sweden.Search for more papers by this authorTajana Tešan Tomić
Sahlgrenska Cancer Center, Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Göteborg, Sweden
Search for more papers by this authorHeléne Gustavsson
Sahlgrenska Cancer Center, Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Göteborg, Sweden
Search for more papers by this authorWanzhong Wang
Sahlgrenska Cancer Center, Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Göteborg, Sweden
Search for more papers by this authorKarin Jennbacken
Sahlgrenska Cancer Center, Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Göteborg, Sweden
Search for more papers by this authorKarin Welén
Sahlgrenska Cancer Center, Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Göteborg, Sweden
Search for more papers by this authorCorresponding Author
Jan-Erik Damber
Sahlgrenska Cancer Center, Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Göteborg, Sweden
Department of Urology, Sahlgrenska University Hospital, Bruna Stråket 11, SE-413 45 Göteborg, Sweden.Search for more papers by this authorAbstract
BACKGROUND
Angiogenesis is important for the progression of prostate cancer and may be a target for treatment in castration resistant (CR) disease. This study was performed to investigate blood vessel stabilization and expression of the pro-angiogenic factors vascular endothelial growth factor (VEGF) and Angiopoietin-2 (Ang-2) in CR and hormone naïve (HN) prostate cancer. The effect of androgen deprivation therapy (ADT) on these parameters was also studied.
METHODS
VEGF and Ang-2, as well as pericyte coverage of blood vessels were studied in HN and CR prostate tumors by immunohistochemistry. The effects of ADT on VEGF expression and microvessel density (MVD) were investigated in biopsies at diagnosis, 3 months after starting ADT and at tumor relapse. Plasma was also analyzed for VEGF and Ang-2 with ELISA.
RESULTS
CR tumors had higher levels of VEGF and Ang-2 as well as increased blood vessel stabilization compared to HN tumors. Three months after initiated ADT an increase of VEGF but not MVD in the tumors was observed. In contrast, plasma levels of VEGF decreased after ADT, and increased again at time of tumor relapse. Ang-2 levels were unaffected.
CONCLUSIONS
CR prostate cancer is associated with elevated levels of VEGF and Ang-2, indicating that these factors could be used as targets for anti-angiogenic treatment. Still, the observed increase in blood vessel stabilization in CR tumors could influence the outcome of anti-angiogenic treatment. Furthermore, increased VEGF expression after 3 months of ADT justifies the use of VEGF-based anti-angiogenic drugs in combination with ADT for the treatment of advanced prostate cancer. Prostate 72:705–712, 2012. © 2011 Wiley Periodicals, Inc.
Supporting Information
Additional Supporting Information may be found in the online version of this article.
| Filename | Description |
|---|---|
| pros_21472_sm_SupplData.doc26.5 KB | Supplementary Data |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1
Strohmeyer D,
Rossing C,
Strauss F,
Bauerfeind A,
Kaufmann O,
Loening S.
Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer.
Prostate
2000;
42(1):
26–33.
10.1002/(SICI)1097-0045(20000101)42:1<26::AID-PROS4>3.0.CO;2-6 CAS PubMed Web of Science® Google Scholar
- 2 Revelos K, Petraki C, Scorilas A, Stefanakis S, Malovrouvas D, Alevizopoulos N, Kanellis G, Halapas A, Koutsilieris M. Correlation of androgen receptor status, neuroendocrine differentiation and angiogenesis with time-to-biochemical failure after radical prostatectomy in clinically localized prostate cancer. Anticancer Res 2007; 27(5B): 3651–3660.
- 3 Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143(2): 401–409.
- 4
Lissbrant IF,
Stattin P,
Damber JE,
Bergh A.
Vascular density is a predictor of cancer-specific survival in prostatic carcinoma.
Prostate
1997;
33(1):
38–45.
10.1002/(SICI)1097-0045(19970915)33:1<38::AID-PROS7>3.0.CO;2-5 CAS PubMed Web of Science® Google Scholar
- 5 Gustavsson H, Welen K, Damber JE. Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis. Prostate 2005; 62(4): 364–373.
- 6 Kosaka T, Miyajima A, Takayama E, Kikuchi E, Nakashima J, Ohigashi T, Asano T, Sakamoto M, Okita H, Murai M, Hayakawa M. Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer. Prostate 2007; 67(1): 41–49.
- 7 Gustavsson HWW, Jennbacken K, Welén K, Damber JE. ADAMTS1, a putative anti-angiogenic factor, is decreased in human prostate cancer. BJU Int 2009; 104(11): 1786–1790.
- 8 Neufeld G, Tessler S, Gitay-Goren H, Cohen T, Levi BZ. Vascular endothelial growth factor and its receptors. Prog Growth Factor Res 1994; 5(1): 89–97.
- 9 Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146(5): 1029–1039.
- 10 Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996; 87(7): 1171–1180.
- 11 Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277(5322): 55–60.
- 12 Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, Yancopoulos GD. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996; 87(7): 1161–1169.
- 13 Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284(5422): 1994–1998.
- 14 Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 2002; 99(17): 11205–11210.
- 15 Helfrich I, Scheffrahn I, Bartling S, Weis J, von Felbert V, Middleton M, Kato M, Ergun S, Schadendorf D. Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp Med 2010; 207(3): 491–503.
- 16 Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999; 103(2): 159–165.
- 17 Franck-Lissbrant I, Haggstrom S, Damber JE, Bergh A. Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology 1998; 139(2): 451–456.
- 18 Stewart RJ, Panigrahy D, Flynn E, Folkman J. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: Evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol 2001; 165(2): 688–693.
- 19
Haggstrom S,
Wikstrom P,
Bergh A,
Damber JE.
Expression of vascular endothelial growth factor and its receptors in the rat ventral prostate and Dunning R3327 PAP adenocarcinoma before and after castration.
Prostate
1998;
36(2):
71–79.
10.1002/(SICI)1097-0045(19980701)36:2<71::AID-PROS1>3.0.CO;2-H CAS PubMed Web of Science® Google Scholar
- 20 Johansson A, Rudolfsson SH, Wikstrom P, Bergh A. Altered levels of angiopoietin 1 and tie 2 are associated with androgen-regulated vascular regression and growth in the ventral prostate in adult mice and rats. Endocrinology 2005; 146(8): 3463–3470.
- 21 Wang GM, Kovalenko B, Huang Y, Moscatelli D. Vascular endothelial growth factor and angiopoietin are required for prostate regeneration. Prostate 2007; 67(5): 485–499.
- 22 Mazzucchelli R, Montironi R, Santinelli A, Lucarini G, Pugnaloni A, Biagini G. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate 2000; 45(1): 72–79.
- 23 Aslan G, Cimen S, Yorukoglu K, Tuna B, Sonmez D, Mungan U, Celebi I. Vascular endothelial growth factor expression in untreated and androgen-deprived patients with prostate cancer. Pathol Res Pract 2005; 201(8–9): 593–598.
- 24 Strohmeyer D, Rossing C, Bauerfeind A, Kaufmann O, Schlechte H, Bartsch G, Loening S. Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate 2000; 45(3): 216–224.
- 25 West AF, O'Donnell M, Charlton RG, Neal DE, Leung HY. Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer. Br J Cancer 2001; 85(4): 576–583.
- 26 Lind AJ, Wikstrom P, Granfors T, Egevad L, Stattin P, Bergh A. Angiopoietin 2 expression is related to histological grade, vascular density, metastases, and outcome in prostate cancer. Prostate 2005; 62(4): 394–399.
- 27 Tesan T, Gustavsson H, Welen K, Damber JE. Differential expression of angiopoietin-2 and vascular endothelial growth factor in androgen-independent prostate cancer models. BJU Int 2008; 102(8): 1034–1039.
- 28 Jones A, Fujiyama C, Turner K, Fuggle S, Cranston D, Bicknell R, Harris AL. Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer. BJU Int 2000; 85(3): 276–280.
- 29 Duque JL, Loughlin KR, Adam RM, Kantoff PW, Zurakowski D, Freeman MR. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999; 54(3): 523–527.
- 30 Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, Kreutzer DL. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: In situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 1997; 157(6): 2329–2333.
- 31 Tanaka F, Ishikawa S, Yanagihara K, Miyahara R, Kawano Y, Li M, Otake Y, Wada H. Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Cancer Res 2002; 62(23): 7124–7129.
- 32 Moon WS, Rhyu KH, Kang MJ, Lee DG, Yu HC, Yeum JH, Koh GY, Tarnawski AS. Overexpression of VEGF and angiopoietin 2: A key to high vascularity of hepatocellular carcinoma? Mod Pathol 2003; 16(6): 552–557.
- 33 Zhang L, Yang N, Park JW, Katsaros D, Fracchioli S, Cao G, O'Brien-Jenkins A, Randall TC, Rubin SC, Coukos G. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res 2003; 63(12): 3403–3412.
- 34 Brown JL, Cao ZA, Pinzon-Ortiz M, Kendrew J, Reimer C, Wen S, Zhou JQ, Tabrizi M, Emery S, McDermott B, Pablo L, McCoon P, Bedian V, Blakey DC. A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol Cancer Ther 2010; 9(1): 145–156.
- 35 Hashizume H, Falcon BL, Kuroda T, Baluk P, Coxon A, Yu D, Bready JV, Oliner JD, McDonald DM. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 2010; 70(6): 2213–2223.
- 36 Welen K, Jennbacken K, Tesan T, Damber JE. Pericyte coverage decreases invasion of tumour cells into blood vessels in prostate cancer xenografts. Prostate Cancer Prostatic Dis 2009; 12(1): 41–46.
- 37 Kelly SH WK, Carducci MA, George DJ, Mahoney JF, Stadler WM, Morris MJ, Kantoff PW, Monk JP III. E. J. Small and Cancer and Leukemia Group B. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 9040. J Clin Oncol 2010; 28(18S): LBA4511 (Meeting Abstract).
- 38 Haggstrom S, Stattin P, Wikstrom P, Bergh A, Damber JE. Castration-induced reduction of vascular endothelial growth factor expression in benign human prostate tissue is lost in advanced prostate cancer. BJU Int 2001; 88(1): 110–116.
- 39 Johansson A, Rudolfsson SH, Kilter S, Bergh A. Targeting castration-induced tumour hypoxia enhances the acute effects of castration therapy in a rat prostate cancer model. BJU Int 2010; 107(11): 1818–1824.
- 40 Mak P, Leav I, Pursell B, Bae D, Yang X, Taglienti CA, Gouvin LM, Sharma VM, Mercurio AM. ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: Implications for Gleason grading. Cancer Cell 2010; 17(4): 319–332.
- 41 Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res 2007; 13(23): 7003–7011.
